Ignite Creation Date:
2025-12-25 @ 12:39 AM
Ignite Modification Date:
2025-12-25 @ 10:50 PM
Study NCT ID:
NCT06109467
Status:
RECRUITING
Last Update Posted:
2025-12-04
First Post:
2023-10-25
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-01-12
Start Date Type:
ACTUAL
Primary Completion Date:
2028-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-04
Completion Date Type:
ESTIMATED
First Submit Date:
2023-10-25
First Submit QC Date:
None
Study First Post Date:
2023-10-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-02
Last Update Post Date:
2025-12-04
Last Update Post Date Type:
ESTIMATED